Infinity to Participate in Wells Fargo and H.C. Wainwright Investor Conferences

Rhea-AI Summary

Infinity Pharmaceuticals (NASDAQ: INFI) announced its participation in two major investor conferences. The Wells Fargo Healthcare Conference will take place on September 9, 2022, featuring a presentation by CEO Adelene Perkins at 8:00 a.m. ET. The H.C. Wainwright Global Investment Conference is set for September 12, 2022, with a virtual presentation available at 7:00 a.m. ET. Infinity is focused on developing eganelisib, an innovative therapeutic targeting immune suppression in cancer. Presentations can be accessed for 90 days post-event on their website.

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Infinity Pharmaceuticals, Inc. (NASDAQ: INFI) (“Infinity” or the “Company”), a clinical-stage biotechnology company developing eganelisib, a first-in-class, oral, immuno-oncology macrophage reprogramming therapeutic, today announced that the Company will present and conduct 1-on-1 meetings with investors at the 2022 Wells Fargo Healthcare Conference and H.C. Wainwright 24^th Annual Global Investment Conference.

2022 Wells Fargo Healthcare Conference
Date: Friday, September 9, 2022
Time: 8:00 a.m. ET
Speaker: Adelene Perkins, Chief Executive Officer
Format: In-person fireside chat and 1-on-1 meetings
Webcast Registration Link

H.C. Wainwright 24^th Annual Global Investment Conference
Date: Monday, September 12, 2022
Time: Presentation available at 7:00 a.m. ET
Speaker: Adelene Perkins, Chief Executive Officer
Format: Virtual company presentation and 1-on-1 meetings
Webcast Registration Link

A replay of the presentations will be available in the Investors/Media section of Infinity's website at www.infi.com for 90 days following the events.

About Infinity and Eganelisib
Infinity Pharmaceuticals, Inc. (“Infinity” or the “Company”), is a clinical-stage biotechnology company developing eganelisib (IPI-549), a first-in-class, oral, immuno-oncology macrophage reprogramming therapeutic which is designed to address a fundamental biologic mechanism of immune suppression in cancer in multiple clinical studies. MARIO-3 is the first eganelisib combination study in front-line advanced cancer patients and is evaluating eganelisib in combination with Tecentriq^® and Abraxane^® in front-line TNBC and in combination with Tecentriq and Avastin^® in front-line RCC. MARIO-275 is a randomized, controlled combination study of eganelisib combined with Opdivo^® in I/O naïve urothelial cancer. For more information on Infinity, please refer to Infinity's website at www.infi.com.

Opdivo^® is a registered trademark of Bristol Myers Squibb.
Tecentriq^® is a registered trademark of Genentech, Inc.
Abraxane^® is a registered trademark of Abraxis BioScience, LLC., a wholly owned subsidiary of Bristol Myers Squibb Company.
Avastin^® is a registered trademark of Genentech, Inc.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220831005151/en/

Investor Relations:

Kevin Lui

Real Chemistry

klui@realchemistry.com

Source: Infinity Pharmaceuticals, Inc.

FAQ

When will Infinity Pharmaceuticals present at the Wells Fargo Healthcare Conference?

Infinity Pharmaceuticals will present at the Wells Fargo Healthcare Conference on September 9, 2022, at 8:00 a.m. ET.

What is the focus of Infinity Pharmaceuticals?

Infinity Pharmaceuticals focuses on developing eganelisib, an oral immuno-oncology therapeutic targeting immune suppression in cancer.

Who will represent Infinity Pharmaceuticals at the investor conferences?

CEO Adelene Perkins will represent Infinity Pharmaceuticals at the investor conferences.

When is the H.C. Wainwright Global Investment Conference?

The H.C. Wainwright Global Investment Conference is scheduled for September 12, 2022.

How long will the presentations from the conferences be available for replay?

The presentations will be available for replay for 90 days on Infinity Pharmaceuticals' website.